N

Nkarta

NKTX

6.41000
USD
-0.03
(-0.47%)
Market Closed
Volume
39,703
EPS
0
Div Yield
0
P/E
-2
Market Cap
293,524,417
Related Instruments
A
ARCT
-1.880
(-8.01%)
21.600 USD
C
CRVS
0.36000
(13.85%)
2.96000 USD
G
GNFT
0.10000
(2.41%)
4.25000 USD
MRNA
-25.020
(-20.99%)
94.160 USD
REGN
13.14
(1.22%)
1,091.19 USD
V
VKTX
-2.380
(-4.18%)
54.610 USD
News

Title: Nkarta

Sector: Healthcare
Industry: Biotechnology
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.